dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Buzón Gómez, María José |
dc.contributor.author | Astorga Gamaza, Antonio |
dc.date.accessioned | 2022-02-24T16:32:33Z |
dc.date.available | 2022-02-24T16:32:33Z |
dc.date.issued | 2021-07 |
dc.identifier.citation | Astorga-Gamaza A, Buzon MJ. The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence. Curr Opin HIV AIDS. 2021 Jul;16(4):193–9. |
dc.identifier.issn | 1746-6318 |
dc.identifier.uri | https://hdl.handle.net/11351/7080 |
dc.description | Marcadors cel·lulars; Virus de la immunodeficiència humana; Persistència viral |
dc.description.sponsorship | This work was supported by the Spanish Secretariat of Science and Innovation and FEDER funds (grants SAF2015-67334-R and RTI2018-101082-B-I00 [MINECO/FEDER]), and the Fundació La Marató TV3 (grant 201805-10FMTV3). M.J.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). A.A.-G. is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016-076382). The funders had no role in the decision to publish or the preparation of the manuscript. |
dc.language.iso | eng |
dc.publisher | Lippincott Williams & Wilkins |
dc.relation.ispartofseries | Current Opinion in HIV and AIDS;16(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Infeccions per VIH - Tractament |
dc.subject | Medicaments antivírics - Ús terapèutic |
dc.subject.mesh | HIV Infections |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antiviral Agents |
dc.subject.mesh | /therapeutic use |
dc.title | The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1097/COH.0000000000000685 |
dc.subject.decs | infecciones por VIH |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antivíricos |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1097/COH.0000000000000685 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 33973900 |
dc.identifier.wos | 000661789900001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2015-67334-R |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/RTI2018-101082-B-I00 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CP17%2F00179 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/BES-2016-076382 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |